Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | RECQL | P46063 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciaftalan SCHEMBL239995 | 0.98 | MEN1 (0.45) | MEN1KMT2ATDP1RECQLTHRB | |
| Ciaftalan SCHEMBL590020 | 0.98 | MEN1 (0.45) | MEN1KMT2ATDP1RECQLTHRB | |
| Ciaftalan SCHEMBL28102961 | 0.98 | MEN1 (0.45) | MEN1KMT2ATDP1RECQLTHRB | |
| Ciaftalan SCHEMBL15992891 | 0.98 | MEN1 (0.45) | MEN1KMT2ATDP1RECQLTHRB | |
| Ciaftalan SCHEMBL51772 | 0.98 | MEN1 (0.45) | MEN1KMT2ATDP1RECQLTHRB | |
| Ciaftalan SCHEMBL28375153 | 0.96 | MEN1 (0.44) | MEN1KMT2ATDP1RECQLTHRB | |
| Ciaftalan SCHEMBL29018905 | 0.96 | MEN1 (0.44) | MEN1KMT2ATDP1RECQLTHRB | |
| Ciaftalan SCHEMBL21834042 | 0.96 | MEN1 (0.44) | MEN1KMT2ATDP1RECQLTHRB | |
| Ciaftalan SCHEMBL10878724 | 0.96 | MEN1 (0.44) | MEN1KMT2ATDP1RECQLTHRB | |
| Ciaftalan SCHEMBL19281364 | 0.96 | MEN1 (0.44) | MEN1KMT2ATDP1RECQLTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-21 | — | — | US | claimed |
| EP-1828174-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-09-05 | — | — | EP | claimed |
| WO-2006054162-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-26 | — | — | WO | claimed |
| CN-110237863-A | A kind of preparation method and applications of three-dimensional porous pomace carbon support Cobalt Phthalocyanine lithium thionyl chloride cell catalysis material | 陕西科技大学 | 2019-09-17 | — | — | CN | disclosed |
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED | 2011-01-27 | — | — | US | disclosed |
| US-7825147-B2 | Inhibitors of phosphodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-02 | — | — | US | disclosed |
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-21 | — | — | US | disclosed |
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | US | disclosed |
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| WO-2006054162-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006035303-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006035280-A1 | 3,4-DIHYDROISOQUINOLINE COMPOUNDS AS MUSCRINIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF RESPIRATORY, URINARY AND GASTROINTESTINAL DISEASES | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
| US-20050075383-A1 | Inhibitors of phophodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-04-07 | — | — | US | disclosed |
| WO-2005021515-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-03-10 | — | — | WO | disclosed |
| US-5859044-A | TREATING DIABETES, HYPERGLYCEMIA, OBESITY; INCREASING CONTENT OF LEAN MEAT IN ANIMALS | PFIZER INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0822185-A1 | B-3-adrenergic agonists as antidiabetic and antiobesity agents | PFIZER INC. (US) | 1998-02-04 | — | — | EP | disclosed |
| US-4372893-A | PREFERENTIAL REDUCTION OF NITRO, NITROSO, OR OXIME GROUPS USING MACROCYCLIC METAL COMPLEX | ECKERT HEINER (DE) | 1983-02-08 | — | — | US | disclosed |
| US-4111933-A | PROTECTION OF FUNCTIONAL GROUPS DURING REACTION AND THEIR SUBSEQUENT RESTORATION | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | PNPO, TPMT, NOD1 | MEN1 3210/4885KMT2A 4273/4885TDP1 435/4885 |
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM5 | MEN1 1762/4885KMT2A 2103/4885TDP1 2243/4885 |
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | PDE4A, PDE4B, PDE4C | MEN1 4688/4885KMT2A 4445/4885TDP1 578/4885 |
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | TLR1, TPMT, NOD1 | MEN1 4171/4885KMT2A 3310/4885TDP1 371/4885 |
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | MEN1 1810/4885KMT2A 3389/4885TDP1 4391/4885 |
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | MEN1 2033/4885KMT2A 1611/4885TDP1 4246/4885 |
| US-20050075383-A1 | Inhibitors of phophodiesterase type-IV | PDE7A, PDE4A, PDE4B | MEN1 4818/4885KMT2A 4537/4885TDP1 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.